Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080875 | 1.00 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL585208 | 0.87 | PARP1 (0.39) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL585011 | 0.87 | PARP1 (0.39) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL27190406 | 0.86 | TOP2A (0.34) | FKBP1ATOP2A | |
| SCHEMBL2842945 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL2842338 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL2838596 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL17930909 | 0.84 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AL3MBTL1ATM | |
| SCHEMBL11975945 | 0.84 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL393307 | 0.83 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-118043316-A | Factor XIIa inhibitors | 卢纳克治疗有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11654197-B2 | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
| WO-2022248883-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2022-12-01 | — | — | WO | disclosed |
| US-20220218830-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218830-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | GABRP, GABRD, GABBR2 | ALDH1A1 1783/4885MEN1 3471/4885KMT2A 1332/4885 |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ALDH1A1 2539/4885MEN1 4454/4885KMT2A 3154/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | ALDH1A1 2539/4885MEN1 4454/4885KMT2A 3154/4885 |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | ALDH1A1 1837/4885MEN1 987/4885KMT2A 793/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ALDH1A1 2539/4885MEN1 4454/4885KMT2A 3154/4885 |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | ALDH1A1 3635/4885MEN1 1335/4885KMT2A 3026/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | ALDH1A1 2173/4885MEN1 4409/4885KMT2A 2949/4885 |
| US-11654197-B2 | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same | GABRP, GABRD, GABBR2 | ALDH1A1 1783/4885MEN1 3471/4885KMT2A 1332/4885 |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | OXA1L, HRH1, OGDH | ALDH1A1 1208/4885MEN1 3613/4885KMT2A 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.